CHICAGO, July 14, 2010 /PRNewswire/ -- ONCURA, a business unit of GE Healthcare and global leader in the minimally invasive permanent prostate brachytherapy management of prostate cancer, has announced that it has signed an agreement to distribute Theragenics Corporation TheraSeed(R) palladium-103 brachytherapy seeds. Under the terms of the agreement, Oncura will exclusively sell the TheraSeed palladium-103 seed, subject to certain pre-existing vendor agreements, for the treatment of prostate cancer in the U.S.

NEW YORK, Sept. 8 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Brachytherapy http://www.reportlinker.com/p0131245/Brachytherapy.html This report analyzes the Global Market for Brachytherapy in Millions of US$.

Theragenics Corporation(R) (NYSE: TGX), a medical device company serving the surgical products and prostate cancer treatment markets, announced today that it completed the acquisition of NeedleTech Products, Inc., on July 28, 2008.

Theragenics Corporation(R) (NYSE: TGX), a medical device company serving the surgical products and prostate cancer treatment markets, announced today that it has signed an agreement to acquire NeedleTech Products, Inc., Attleboro, MA, a privately held manufacturer of specialty needles and related medical devices, for $47.8 million in cash, subject to adjustment.

Theragenics Corporation, a medical device Company serving the prostate cancer and surgical markets (NYSE: TGX), is challenging men to engage in a national debate surrounding the treatment of the disease that will affect one in six of them - prostate cancer.